Immune monitoring technology primer: immunoprofiling of antigen-stimulated blood by unknown
SHORT REPORT Open Access
Immune monitoring technology primer:
immunoprofiling of antigen-stimulated
blood
Laura Rosa Brunet1*, Samuel LaBrie2 and Thorsten Hagemann1
Name(s) of the technology
TruCulture® Whole Blood Collection and Culture system
is a whole blood collection and stimulation platform
from Myriad RBM (Austin, USA).
Description of the technology
Compelling evidence from several studies on the im-
mune contexture of the tumor has revealed that infiltra-
tion by specific leukocyte cell subsets with specific
cytokine signatures is linked with favorable outcomes in
a variety of different cancers [1, 2]. Given the potential
burden and limitation of repeat biopsies, there is a need
for non-invasive techniques to complement the
characterization of the immune contexture within the
tumor and provide prognostic biomarkers for use in
clinical immune monitoring. Advances in genomics, pro-
teomics and metabolomics offer promise but have not
yet translated to significant progress in this area. Never-
theless circulatory immunological biomarkers could po-
tentially aid clinical decision-making regarding initiation,
cessation, escalation or change of treatment and assess-
ment of therapeutic responses. Moreover, in the context
of immunotherapy, immunological biomarkers could
serve as indicators of immunological competence and
therefore susceptibility to immune-based therapies. As
the success of immunotherapies is dependent on a func-
tioning immune system and the development and/or
restoration of anti-tumor adaptive immune responses,
determining the level of the patient immune competency
prior to or during immunotherapy may be critical. This
assessment can be based on changes in secretion of both
T-cell derived or APC-secreted cytokines and chemo-
kines under specific stimulatory conditions and may
ultimately help guide clinical choices.
The TruCulture® system is a syringe-based device de-
signed for point of care use, allowing for sterile collec-
tion of whole blood (Fig. 1). The tube contains 1 ml of
cell culture medium which may include a variety of im-
munological stimulants aimed at different cell subsets
(Table 1). In these tubes, similar to blood collection
tubes, 1 ml of whole blood is drawn in and mixed with
the medium. Control tubes with no stimulants to assess
background levels of mediators of interest are included.
The tube is incubated at 37 °C in a dry heat-block for 24
to 48 h. After incubation, cells are separated by a valve
separator component. The supernatant, now free of cells,
is stored at −80 °C until analysis. This process does not
require access to laboratory equipment such as sterile
hood, CO2 incubator, centrifuge etc. or specialized train-
ing, so it has the potential to become a research tool
easily integrated into clinical trial protocols and per-
formed at point of care by nursing staff.
This technique may be considered an improvement
over the more involved laboratory processes used to ob-
tain Peripheral Blood Mononuclear Cells (PBMC) for in
vitro culture or over whole blood stimulation assays.
Compared to PBMC assays, the TruCulture® accurately
represents responsiveness to immune stimuli by human
whole blood immune cells as it maintains in its mix all
type of immune cells present in the blood, including
granulocytes and platelets. Moreover, it is not dependent
on cryopreservation as it is often the case with PBMC
assays. Furthermore, by relying on a self-enclosed tube is
not susceptible to contamination during handling. The
available experimental data provided by the manufac-
turer indicate that the number of cytokines and their se-
creted levels are similar between TruCulture® and PBMC
assays [3]. Compared to whole blood stimulation assays
which rely on a relatively short time in culture, the lon-
ger incubation periods of the TruCulture® system per-
mits investigation of processes involving both de novo
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Fig. 1 Workflow TruCulture® Whole Blood Collection and Culture system
Table 1 Stimulants currently available for the TruCulture® Whole Blood Collection and Culture system
Description of stimulant Target
Null TruCulture (TC) tube (TC Tubes Null) Control
Tumor Necrosis factor (TNF)-alpha tube (TC Tubes TNF-α 10 ng/ml) Cytokine
Intron A/Interferon (IFN)-alpha tube (TC Tubes IFN-α) Cytokine
Interferon (IFN)-beta tube (TC Tubes IFN-β) Cytokine
Interleukin (IL)-1beta + TNF-α tube (TC Tubes IL-1β + TNF-α) Cytokine
Intron A/IFN-α + anti-CD3 + anti-CD28 tube (TC Tubes IFN-α + CD3 + CD28) Cytokine
Intron A/IFN-α + Lipopolysaccharide (LPS)-EB (Escherichia coli 0111:B4) high concentration tube
(TC Tubes IFN-α + LPS-EB)
Cytokine/TLR4 Ligand
Adenosine Triphosphate (ATP) + LPS-EB tube (TC Tubes ATP + LPS-EB) NLRP3 Inflammasome/TLR4 Ligand
Lauroyl-γ-D-glutamyl-meso-diaminopimelic acid (C12-iE-DAP) tube (TC Tubes C12-iE-DAP) NOD Ligand
Lipoarabinomannan (LAM) from M. smegmatis tube (TC Tubes LAM-MS) NOD Ligand
Staphylococcal Enterotoxin B (SEB) tube (TC Tubes SEB) T-Cell
Anti-CD3/CD28 tube (TC Tubes CD3 + CD28) T-Cell
SEB/anti-CD28 tube (TC Tubes SEB + CD28) T-Cell
anti- CD3 tube (TC Tubes CD3) T-Cell
Zymosan (ZYM) tube (TC Tubes ZYM) TLR2 Ligand
Fibroblast-stimulating Lipopeptide (FSL) tube (TC Tubes FSL-1) TLR2 Ligand
Heat killed E. coli 0111:B4 tube (TC Tubes HKEB) TLR2 Ligand
Heat Killed Lactobacillus rhamnosus tube (TC Tubes HKLR) TLR2 Ligand
Polyinosinic:polycytidylic acid (Poly I:C) tube (TC Tubes Poly I:C) TLR3 Ligand
LPS tube (TC Tubes LPS) TLR4 Ligand
LPS-EB high concentration tube (TC Tubes LPS-EB) TLR4 Ligand
LPS + SEB tube (TC Tubes LPS + SEB) TLR4 Ligand/T-Cell
Resiquimod R848 tube (TC Tubes R848) TLR7/8 Ligand
Gardiquimod (GDQ) tube (TC Tubes GDQ) TLR7/8 Ligand
Class A CpG oligonucleotide + LPS-EB high concentration tube (TC Tubes ODN2216 + LPS-EB) TLR9 Ligand
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cytokine and chemokine synthesis and for accumulation
of mediators for more robust measurements [3].
Accessing whole blood, as described in this approach,
may offer a way to identify peripheral biomarkers for pa-
tient clinical assessment. It is not taxing for patients as
only small blood volumes are required and the ease of
handling of the samples is easily integrated with routine
clinical sample processing.
Type of data obtained/readout
Analysis can be based on any technique which detects
immunological mediators in culture supernatants, ran-
ging from ELISA to multiplex analysis, to allow for max-
imal data acquisition. Using TruCulture® can aid in the
identification of circulatory biomarkers that may offer
information on patient prognosis as important as that
provided by the immunoscore at the tumor site [1, 2].
Furthermore characterization of relevant circulatory
biomarkers may prove to be critical for non-invasive
monitoring disease progression and response to immu-
notherapeutic treatments.
In healthy volunteers, this technique has been used to
successfully quantify circulatory immunological media-
tors [4–7]. In particular, Mueller and colleagues showed
(by ELISA) reproducible subject-specific cytokine refer-
ence patterns in healthy individuals, which remained
consistent over time [4]. Duffy and colleagues, in an
exhaustive study published in Immunity in 2015, were
able to differentiate (using Luminex multianalyte pro-
filing) specific inflammatory signatures based on 32
measured mediators for each of the 27 stimulants
contained in the TruCulture® tubes they tested with
blood from 25 subjects [5].
Limitations of the approach
For correct interpretation, a negative control tube (i.e.
Null) should be included to provide an assessment of
the background levels of immunological markers.
Whereas the list of off-the-shelf stimulants is increasing,
there may be still limitations to their relevance to spe-
cific clinical investigations in the oncology field. Given
the one-year expiry date on the tubes, it may be that
over the course of a clinical trial, a number of tube
lots are used. However, equivalence data between dif-
ferent lots can be requested. Tube usage has to be
significantly overestimated to account for potential
clinical trial issues such as delays in patient recruit-
ment, timing of sampling etc.
Types of samples needed and special issues
pertaining to samples
Proper collection, incubation and storage at −80 °C of
samples are critical, but the limited requirement for ma-
nipulation provides a significant advantage. The use of a
null tube allows for the control of the effects of thera-
peutic agents present in the whole blood which may in-
fluence data interpretation. The usual care applied to
supernatant samples needs to be followed including
limitation of freeze-thawing cycles and all samples per-
taining to a single patients being run at the same time to
limit inter-assay variation.
Level of evidence
The level of evidence for this rather novel technique is
currently limited to published studies in healthy individ-
uals. These studies reported the successful quantification
of immunological mediators and identification of specific
immunological signatures for each of the stimulants
used [4–7]. Published papers in patients are limited to
first-onset schizophrenia, where analysis of TruCulture®
supernatants revealed a distinctive pro-inflammatory sig-
nature characterized by altered endothelial cell function
and inflammation [8].
There have yet to be any formal published studies
using TruCulture® in cancer patients. However, the tech-
nology is being increasingly used and reported [7, 9]. For
example, we have presented initial data from selected
colorectal and pancreatic cancer patients showing that
this technique offers a way of reliably obtaining measur-
able immunological responses in patients before and
after therapy with IMM-101, an immunotherapeutic
agent based on Mycobacterium obuense (NCTC 13365),
used in combination with standard chemotherapy or ra-
diation therapy [9]. In contrast, multiplex analysis of pa-
tients’ serum samples detects only very low levels of the
secreted and systemically circulating cytokines. This is
because when using TruCulture®, stimulated immune
cells secrete a more varied range of detectable immuno-
logical mediators, and levels remains high as they do not
become diluted in the serum.
In the future, this approach, characterized by low bur-
den for patients providing samples and ease of use for
clinical staff, may become increasingly adopted to moni-
tor patient’s immunological responses so that research in
this area may eventually identify prognostic biomarkers
to complement those identified at the tumor site.
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